PFIZER INC — Director's Dealing 2020

Oct 29, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Cerevel Therapeutics Holdings, Inc. (CERF)
CIK: 0001805387
Period of Report: 2020-10-27

Reporting Person: PFIZER INC (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	26149211	Direct

Footnotes

F1: On October 27, 2020, Cerevel Therapeutics Holdings, Inc. (f/k/a ARYA Sciences Acquisition Corp II, the "Issuer") consummated a business combination (the "Business Combination") pursuant to which Cassidy Merger Sub 1, Inc., a wholly-owned subsidiary of the Issuer merged with and into Cerevel Therapeutics, Inc. ("Cerevel"). At the effective time of the Business Combination, each share of Cerevel outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an implied Cerevel vested equity value of $780,000,000. As a result, Pfizer Inc. received 26,149,211 shares of the Issuer's Common Stock in consideration for the equity securities of Cerevel held by Pfizer Inc. prior to the Business Combination.